BioLife Solutions Stock Forecast, Price & News

BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions

Is BioLife Solutions a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioLife Solutions stock.
View analyst ratings for BioLife Solutions or view top-rated stocks.

How has BioLife Solutions' stock been impacted by Coronavirus (COVID-19)?

BioLife Solutions' stock was trading at $12.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLFS stock has increased by 225.6% and is now trading at $39.88.
View which stocks have been most impacted by COVID-19.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Monday, March 28th 2022.
View our earnings forecast for BioLife Solutions.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings data on Thursday, November, 11th. The medical equipment provider reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.21. The medical equipment provider earned $33.80 million during the quarter, compared to analyst estimates of $31.65 million. BioLife Solutions had a net margin of 4.87% and a negative trailing twelve-month return on equity of 2.39%. During the same period in the prior year, the company posted ($0.02) EPS.
View BioLife Solutions' earnings history.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions issued an update on its FY 2021 earnings guidance on Thursday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $115 million-$119 million, compared to the consensus revenue estimate of $114.44 million.

What price target have analysts set for BLFS?

7 brokers have issued 12-month price targets for BioLife Solutions' stock. Their forecasts range from $54.00 to $65.00. On average, they expect BioLife Solutions' stock price to reach $59.86 in the next twelve months. This suggests a possible upside of 50.1% from the stock's current price.
View analysts' price targets for BioLife Solutions or view top-rated stocks among Wall Street analysts.

Who are BioLife Solutions' key executives?

BioLife Solutions' management team includes the following people:

• Michael P. Rice, Chairman & Chief Executive Officer
• Maurice H. Tenney, President & Chief Operating Officer
• Roderick de Greef, Secretary & Chief Financial Officer
• Aby J. Mathew, Chief Scientific Officer & Executive VP
• Karen Foster, Chief Quality Officer (LinkedIn Profile)

What is Mike Rice's approval rating as BioLife Solutions' CEO?

5 employees have rated BioLife Solutions CEO Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among BioLife Solutions' employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BioLife Solutions' key competitors?

Some companies that are related to BioLife Solutions include InMode (INMD), LivaNova (LIVN), CONMED (CNMD), Outset Medical (OM), ViewRay (VRAY), Natus Medical (NTUS), Cutera (CUTR), Semler Scientific (SMLR), TransMedics Group (TMDX), Zynex (ZYXI), Stereotaxis (STXS), AxoGen (AXGN), Edap Tms (EDAP), Movano (MOVE) and FONAR (FONR).
View all of BLFS's competitors.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include (CGC), Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional shareholders include Casdin Capital LLC (18.59%), BlackRock Inc. (10.39%), Geneva Capital Management LLC (3.22%), Marshall Wace LLP (3.18%), Invesco Ltd. (1.49%) and Wasatch Advisors Inc. (1.17%). Company insiders that own BioLife Solutions stock include Aby J Mathew, Aby J Mathew, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard and Walter Villiger.
View institutional ownership trends for BioLife Solutions.

Which major investors are selling BioLife Solutions stock?

BLFS stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Millennium Management LLC, Marshall Wace LLP, Russell Investments Group Ltd., Gagnon Securities LLC, TimesSquare Capital Management LLC, Sentinel Pension Advisors Inc., and American Financial Group Inc.. Company insiders that have sold BioLife Solutions company stock in the last year include Aby J Mathew, Andrew G Hinson, Greef Roderick De, Joseph C Schick, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Sarah Aebersold, Todd Berard, and Walter Villiger.
View insider buying and selling activity for BioLife Solutions or view top insider-selling stocks.

Which major investors are buying BioLife Solutions stock?

BLFS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Geneva Capital Management LLC, Moody Aldrich Partners LLC, Principal Financial Group Inc., Bank of New York Mellon Corp, Bard Financial Services Inc., Casdin Capital LLC, and Invesco Ltd..
View insider buying and selling activity for BioLife Solutions or or view top insider-buying stocks.

How do I buy shares of BioLife Solutions?

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $39.88.

How much money does BioLife Solutions make?

BioLife Solutions has a market capitalization of $1.62 billion and generates $48.09 million in revenue each year. The medical equipment provider earns $2.67 million in net income (profit) each year or $0.10 on an earnings per share basis.

How many employees does BioLife Solutions have?

BioLife Solutions employs 196 workers across the globe.

What is BioLife Solutions' official website?

The official website for BioLife Solutions is www.biolifesolutions.com.

Where are BioLife Solutions' headquarters?

BioLife Solutions is headquartered at 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at (425) 402-1400, via email at [email protected], or via fax at 425-402-1433.